Well-Known Japanese Medicine Exposed for 30 Years of Data Falsification

News

Well-Known Japanese Medicine Exposed for 30 Years of Data Falsification

Well-Known Japanese Medicine Exposed for 30 Years of Data Falsification

According to a report by Japan’s Yomiuri Shimbun on April 27th, the manufacturer of the well-known medicine Seirogan, Japan Kyotou Co., Ltd., has been exposed for falsifying data for 30 consecutive years. The local government has ordered the company to suspend production and sales of this medicine.

Records show that Seirogan has a history of over 100 years and has been promoted for its “treatment of gastrointestinal discomfort,” selling well in Japan and overseas.

The report cited a notification from the Toyama Prefectural Government, where Kyotou Co., Ltd. is located, stating that during a recent surprise inspection, it was found that the effective ingredients in the medicine were significantly different from the advertised efficacy. What’s worse, in order to conceal the truth, Kyotou Co., Ltd. has been tampering with experimental data for the past 30 years, allowing Seirogan to pass inspections and be marketed.

Well-Known Japanese Medicine Exposed for 30 Years of Data Falsification

Regarding the inspection results, Kyotou Co., Ltd. admitted and apologized to consumers. As of now, the company has voluntarily recalled 5.16 million units of Seirogan that have been distributed to the market.

Currently, based on the Japanese Pharmaceutical and Medical Devices Act, the Toyama Prefectural Government has ordered Kyotou Co., Ltd. to suspend sales on the 22nd and production on the 23rd starting from April 30th.

Recently, there have been continuous controversies involving Japanese pharmaceutical companies. According to previous reports, a health product containing red yeast rice produced by the well-known Japanese pharmaceutical company Kobayashi Pharmaceutical has caused a major uproar, resulting in health damage to consumers. As of April 24th, five people have died and 257 people have been hospitalized after taking the company’s implicated health product.